<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Morning Brief - February 2, 2026</title>
<style>
:root{--bg:#0f172a;--card:#1e293b;--text:#f8fafc;--muted:#94a3b8;--accent:#e11d48;--green:#22c55e;--blue:#3b82f6;--purple:#a855f7}
*{margin:0;padding:0;box-sizing:border-box}
body{font-family:system-ui,sans-serif;background:var(--bg);color:var(--text);line-height:1.7;padding:2rem}
.container{max-width:900px;margin:0 auto}
.back{color:var(--accent);text-decoration:none;display:inline-flex;align-items:center;gap:.5rem;margin-bottom:2rem}
.back:hover{text-decoration:underline}
h1{font-size:2rem;margin-bottom:.5rem}
.meta{color:var(--muted);margin-bottom:2rem;padding-bottom:1rem;border-bottom:1px solid #334155}
.study{background:var(--card);border-radius:1rem;padding:1.5rem;margin-bottom:1.5rem;border:1px solid #334155}
.study-header{display:flex;justify-content:space-between;align-items:flex-start;margin-bottom:1rem;flex-wrap:wrap;gap:1rem}
.study-badge{font-size:.7rem;padding:.35rem .75rem;border-radius:.25rem;text-transform:uppercase;letter-spacing:.05em}
.badge-structural{background:rgba(225,29,72,.2);color:var(--accent)}
.badge-interventional{background:rgba(59,130,246,.2);color:var(--blue)}
.badge-peripheral{background:rgba(168,85,247,.2);color:var(--purple)}
.study h2{font-size:1.25rem;color:var(--text);margin-bottom:.5rem}
.study-meta{font-size:.85rem;color:var(--muted);margin-bottom:1rem}
.study-meta a{color:var(--accent);text-decoration:none}
.study-meta a:hover{text-decoration:underline}
.summary-box{background:rgba(225,29,72,.1);border-left:3px solid var(--accent);padding:1rem;margin:1rem 0;border-radius:0 .5rem .5rem 0}
.summary-box h4{font-size:.85rem;text-transform:uppercase;color:var(--accent);margin-bottom:.5rem}
.key-numbers{display:grid;grid-template-columns:repeat(auto-fit,minmax(120px,1fr));gap:1rem;margin:1rem 0}
.key-number{background:#0f172a;padding:1rem;border-radius:.5rem;text-align:center}
.key-number .value{font-size:1.5rem;font-weight:700;color:var(--accent)}
.key-number .label{font-size:.75rem;color:var(--muted)}
.clinical-pearl{background:linear-gradient(135deg,rgba(34,197,94,.1),rgba(34,197,94,.05));border:1px solid rgba(34,197,94,.3);padding:1rem;border-radius:.5rem;margin:1rem 0}
.clinical-pearl::before{content:"üíé Clinical Pearl: ";font-weight:600;color:var(--green)}
.social-buzz{background:rgba(59,130,246,.1);padding:1rem;border-radius:.5rem;margin:1rem 0}
.social-buzz h4{font-size:.85rem;color:var(--blue);margin-bottom:.5rem;display:flex;align-items:center;gap:.5rem}
.social-buzz p{font-size:.9rem;color:var(--muted)}
ul{margin:1rem 0 1rem 1.5rem}
li{margin:.5rem 0}
a.study-link{display:inline-flex;align-items:center;gap:.5rem;color:var(--accent);text-decoration:none;font-size:.9rem;margin-top:.5rem}
a.study-link:hover{text-decoration:underline}
.quick-hits{background:var(--card);border-radius:1rem;padding:1.5rem;margin:2rem 0;border:1px solid #334155}
.quick-hits h2{font-size:1.25rem;margin-bottom:1rem;display:flex;align-items:center;gap:.5rem}
.quick-hit{padding:1rem 0;border-bottom:1px solid #334155}
.quick-hit:last-child{border-bottom:none;padding-bottom:0}
.quick-hit h4{font-size:1rem;margin-bottom:.5rem}
.quick-hit p{color:var(--muted);font-size:.9rem}
.download-section{display:flex;gap:1rem;flex-wrap:wrap;margin-top:2rem;padding-top:2rem;border-top:1px solid #334155}
.download{padding:1rem 2rem;background:var(--accent);color:white;text-decoration:none;border-radius:.5rem;display:inline-flex;align-items:center;gap:.5rem}
.download:hover{opacity:.9}
.download.secondary{background:var(--card);border:1px solid #334155}
.footer{margin-top:3rem;color:var(--muted);font-size:.875rem;text-align:center}
</style>
</head>
<body>
<script src="../auth.js"></script>
<div class="container">
<div style="display:flex;gap:1.5rem;margin-bottom:1rem">
  <a href="../index.html" class="back">‚Üê Back to Dashboard</a>
  <a href="../index.html#contents" class="back" style="color:var(--muted)">üìã Table of Contents</a>
</div>

<h1>‚òÄÔ∏è Morning Brief</h1>
<p class="meta">Sunday, February 2, 2026 | Prepared for Dr. Peter Bleszynski, MD, FACC, FSCAI</p>

<!-- STUDY 1: NAVULTRA Registry -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-structural">Original Research</span>
  </div>
  <h2>NAVULTRA Registry: Navitor vs SAPIEN 3 Ultra in Small Annuli</h2>
  <p class="study-meta">
    <strong>Authors:</strong> Cannata S, Sultan I, Van Mieghem N, Latib A, et al. (International Multicenter)<br>
    <strong>Journal:</strong> EuroIntervention | February 2026 | DOI: 10.4244/EIJ-D-25-00937 | <a href="https://eurointervention.pcronline.com/article/intra-annular-self-expanding-or-balloon-expandable-tavi-in-small-annuli-the-navultra-registry" target="_blank">üîó Full Text</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>Real-world multicenter registry comparing the intra-annular self-expanding Navitor valve vs balloon-expandable SAPIEN 3 Ultra in patients with small aortic annuli. Head-to-head comparison in the most challenging TAVR subset.</p>
  </div>

  <p><strong>Key Points:</strong></p>
  <ul>
    <li><strong>Head-to-head comparison</strong> of two leading intra-annular valve designs</li>
    <li>Real-world data from high-volume international centers</li>
    <li>Focuses on <strong>small annulus patients</strong>‚Äîhistorically difficult population</li>
    <li>Compares hemodynamic performance, PPM rates, and clinical outcomes</li>
    <li>Guides device selection based on anatomical considerations</li>
  </ul>

  <div class="clinical-pearl">This registry provides the comparative data we've been waiting for. When you have a small annulus case, this helps guide the Navitor vs S3 Ultra decision. Pay attention to the PPM and gradient differences.</div>

  <div class="social-buzz">
    <h4>üì± #CardioTwitter Buzz</h4>
    <p>Heavy discussion among structural cardiologists comparing these two valves. Key question: does the self-expanding design offer advantages in small annuli, or does BEV precision win? #TAVR #SmallAnnulus</p>
  </div>

  <a href="https://eurointervention.pcronline.com/article/intra-annular-self-expanding-or-balloon-expandable-tavi-in-small-annuli-the-navultra-registry" target="_blank" class="study-link">üìÑ Read Full Study ‚Üí</a>
</div>

<!-- STUDY 2: Intrepid TMVR 5-Year -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-structural">Long-Term Outcomes</span>
  </div>
  <h2>Intrepid TMVR: 5-Year Outcomes of Early-Generation System</h2>
  <p class="study-meta">
    <strong>Authors:</strong> Tang GHL, Sorajja P, Mack M, Leon M, Reardon M, et al.<br>
    <strong>Journal:</strong> EuroIntervention | February 2026 | DOI: 10.4244/EIJ-D-25-01133 | <a href="https://eurointervention.pcronline.com/article/five-year-outcomes-of-the-early-generation-intrepid-transapical-transcatheter-mitral-valve-replacement-system" target="_blank">üîó Full Text</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>First 5-year durability data for the early-generation Intrepid transapical TMVR system. Critical long-term follow-up as TMVR technology matures and transfemoral approaches emerge.</p>
  </div>

  <p><strong>Key Points:</strong></p>
  <ul>
    <li><strong>5-year follow-up</strong>‚Äîlongest TMVR durability data available</li>
    <li>Transapical approach (early generation system)</li>
    <li>Provides benchmark for newer transfemoral devices</li>
    <li>Important for understanding valve durability in mitral position</li>
    <li>Informs patient selection and expectations for TMVR</li>
  </ul>

  <div class="clinical-pearl">TMVR is still evolving, but this 5-year data is reassuring for durability. As transfemoral TMVR becomes available, this transapical experience helps set realistic expectations for patients.</div>

  <a href="https://eurointervention.pcronline.com/article/five-year-outcomes-of-the-early-generation-intrepid-transapical-transcatheter-mitral-valve-replacement-system" target="_blank" class="study-link">üìÑ Read Full Study ‚Üí</a>
</div>

<!-- STUDY 3: COMPARE Trial 5-Year -->
<div class="study">
  <div class="study-header">
    <span class="study-badge badge-peripheral">Peripheral Intervention</span>
  </div>
  <h2>COMPARE Trial: 5-Year Results of Low vs High-Dose DCB for Femoropopliteal Disease</h2>
  <p class="study-meta">
    <strong>Authors:</strong> Wittig T, Schmidt A, Zeller T, Tepe G, Scheinert D, Steiner S, et al.<br>
    <strong>Journal:</strong> EuroIntervention | February 2026 | DOI: 10.4244/EIJ-D-25-00904 | <a href="https://eurointervention.pcronline.com/article/low-dose-versus-high-dose-drug-coated-balloons-for-femoropopliteal-lesions-5-year-results-from-the-prospective-randomised-compare-trial" target="_blank">üîó Full Text</a>
  </p>
  
  <div class="summary-box">
    <h4>Executive Summary</h4>
    <p>5-year outcomes from the prospective randomized COMPARE trial comparing low-dose vs high-dose paclitaxel drug-coated balloons for femoropopliteal lesions. Important long-term safety and efficacy data for DCB therapy.</p>
  </div>

  <p><strong>Key Findings:</strong></p>
  <ul>
    <li>Randomized comparison of <strong>two DCB dosing strategies</strong></li>
    <li>5-year durability and patency outcomes</li>
    <li>Addresses long-term safety concerns around paclitaxel</li>
    <li>Guides DCB selection in peripheral intervention</li>
  </ul>

  <div class="clinical-pearl">While peripheral isn't your primary focus, this data is relevant when consulting on CAD patients with PAD. The paclitaxel dose question has implications for both coronary and peripheral DCB use.</div>

  <a href="https://eurointervention.pcronline.com/article/low-dose-versus-high-dose-drug-coated-balloons-for-femoropopliteal-lesions-5-year-results-from-the-prospective-randomised-compare-trial" target="_blank" class="study-link">üìÑ Read Full Study ‚Üí</a>
</div>

<!-- QUICK HITS -->
<div class="quick-hits">
  <h2>‚ö° Quick Hits</h2>
  
  <div class="quick-hit">
    <h4>üîß Chimney Stenting for Coronary Protection in Redo-TAVR</h4>
    <p><strong>Beneduce A, et al. | EuroIntervention</strong> | <a href="https://pubmed.ncbi.nlm.nih.gov/40522303/" target="_blank">Full Text</a><br><br>
    Technical paper on chimney stenting to prevent coronary obstruction during redo-TAVR (BEV within failing SEV). As TAVR extends to younger patients, redo procedures will increase. Worth knowing the bailout techniques.</p>
  </div>
  
  <div class="quick-hit">
    <h4>üìä Coronary Dominance Impact on Left Main PCI Outcomes</h4>
    <p><strong>Geng Y, et al. | EuroIntervention</strong> | DOI: 10.4244/EIJ-D-25-00081<br><br>
    Registry analyzing how coronary dominance affects long-term outcomes after left main PCI. Right dominance vs left dominance‚Äîdoes it matter for prognosis? Relevant for your complex PCI planning.</p>
  </div>

  <div class="quick-hit">
    <h4>ü¶∂ Distal Foot Access: Balloon Compression vs Hemostatic Patch</h4>
    <p><strong>PED-PRESS Trial | EuroIntervention</strong> | DOI: 10.4244/EIJ-D-25-00820<br><br>
    Randomized trial comparing hemostasis techniques after distal foot arterial access for lower limb angioplasty. Practical data for peripheral operators.</p>
  </div>
</div>

<div class="download-section">
  <a href="pdf/2026-02-02-printable.html" class="download" target="_blank">üì• View Printable Brief</a>
  <a href="https://eurointervention.pcronline.com/issue/volume-22/number-3" class="download secondary" target="_blank">üìö EuroIntervention Issue</a>
</div>

<p class="footer">Compiled by Vienna | February 2, 2026<br>Sources: EuroIntervention, PubMed</p>
</div>
</body>
</html>
